Liquid Biopsy-Guided Therapy Improves Survival in Lung Cancer
Targeted therapy was associated with better survival with both ctDNA and tissue-only matched patients.
Diagnosis & Disease Information
Less Than Half of NSCLC Patients Received Comprehensive Biomarker Testing in a Real-World Study
Most patients had at least 1 biomarker test, but only 46% had all 5 biomarker tests.
Antibody-Drug Conjugate Proves Active in Advanced, Resistant EGFR-Mutated Lung Cancer
Responses were observed across EGFR TKI resistance mechanisms.
Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus
The median PFS was 8.5 months in the pasireotide arm, 12.5 months in the everolimus arm, and 16.5 months in the combination arm.
PD-L1 Expression in Macrophage-Like Cells Linked to PFS After Immunotherapy in Non-Small Cell Lung Cancer
The size of cancer-associated macrophage-like cells was linked to progression-free survival as well.
No Survival Difference With Once-Daily vs Twice-Daily Radiotherapy in Small Cell Lung Cancer
Overall and progression-free survival were similar between the treatment arms.
- Loading...
Loading...
Next post in ASCO 2021 Lung Cancer In-depth
Loading... 
Loading...